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Lyme disease, a chronic multisystemic disorder that can affect the skin, heart, joints, and nervous system is
caused by Borrelia burgdorferi sensu lato. Lyme disease spirochetes were previously shown to bind glycosamino-
glycans (GAGs). In the current study, the GAG-binding properties of eight Lyme disease strains were deter-
mined. Binding by two high-passage HB19 derivatives to Vero cells could not be inhibited by enzymatic removal
of GAGs or by the addition of exogenous GAG. The other six strains, which included a different high-passage
HB19 derivative (HB19 clone 1), were shown to recognize both heparan sulfate and dermatan sulfate in cell-
binding assays, but the relative efficiency of binding to these two GAGs varied among the strains. Strains N40,
CA20-2A, and PBi bound predominantly to heparan sulfate, PBo bound both heparan sulfate and dermatan
sulfate roughly equally, and VS461 and HB19 clone 1 recognized primarily dermatan sulfate. Cell binding by
strain HB19 clone 1 was inhibited better by exogenous dermatan sulfate than by heparin, whereas heparin was
the better inhibitor of binding by strain N40. The GAG-binding preference of a Lyme disease strain was reflected
in its cell-type-specific binding. Strains that recognized predominantly heparan sulfate bound efficiently to
both C6 glioma cells and EA-Hy926 cells, whereas strains that recognized predominantly dermatan sulfate
bound well only to the glial cells. The effect of lyase treatment of these cells on bacterial binding was consistent
with the model that cell-type-specific binding was a reflection of the GAG-binding preference. We conclude that
the GAG-binding preference varies with the strain of Lyme disease spirochete and that this variation influences
cell-type-specific binding in vitro.
Lyme borreliosis, caused by the spirochete Borrelia burgdor-
feri sensu lato, is a chronic, multisystemic illness found in Eu-
rope, Asia, and North America (30). The bacterium is intro-
duced into the human host by the bite of the Ixodes tick, and
local infection of the skin results in the characteristic rash,
erythema migrans. After this local infection, the spirochete can
disseminate via the blood to other sites, including the joints,
heart, nervous system, and skin. The bacterium can survive for
long periods of time in some of these tissues, giving rise to
chronic manifestations of Lyme disease, such as arthritis, neu-
roborreliosis, and acrodermatitis.
The molecular mechanisms that promote the infection of
specific tissues by the spirochete or its survival in the mamma-
lian hosts are not well understood. The adherence of bacteria
to host tissues is the first step in the establishment of many
infections (10), and B. burgdorferi is known to attach to a wide
variety of cell types in vitro, such as lymphocytes (7), platelets
(11), epithelial cells (32), endothelial cells (6, 31), and neuro-
glia (13). B. burgdorferi recognizes several classes of host cell
components, including integrins (3, 4), glycolipids (12), and
proteoglycans (15, 17, 22, 24).
Proteoglycans are composed of a protein core covalently
linked to glycosaminoglycans (GAGs). GAGs are long, linear,
highly sulfated heteropolymers of hexosamine residues alter-
nating with another sugar, usually a uronic acid (20, 29). Based
on the identity of the hexosamine, the common GAG chains
are divided into two groups, glucosaminoglycans and galactos-
aminoglycans. Each group can be further subdivided into dif-
ferent classes on the basis of epimerization of the glycan chain
and the extent and location of the sulfate groups. Thus, hepa-
ran sulfate (and the more highly sulfated model analog, hep-
arin) is a glucosaminoglycan, while chondroitin-4-sulfate (also
known as chondroitin sulfate A), chondroitin-6-sulfate (chon-
droitin sulfate C), and dermatan sulfate (chondroitin sulfate
B) comprise the galactosaminoglycans. The different classes of
GAGs are often distinguished from each other experimentally
on the basis of their sensitivity to different lyases (20).
Several isolates of B. burgdorferi recognize heparan sulfate
and dermatan sulfate for cell binding (17, 22, 24). GAGs are
ubiquitously expressed by mammalian cells and thus could
promote bacterial attachment to many tissues colonized by B.
burgdorferi. Consistent with this hypothesis, GAGs were shown
to promote binding of B. burgdorferi N40 clone D10/E9 to
diverse cell types in vitro, including endothelial, glial, and neu-
ronal cells (24). The particular class of GAG that was critical
for bacterial attachment, however, varied with cell type:hep-
aran sulfate mediated attachment to endothelial cells, while
both heparan sulfate and dermatan sulfate participated in at-
tachment to glial cells (24). In the current study, we examined
the recognition of GAGs by several strains of Lyme disease
spirochete. The results indicate that GAG-binding preferences
vary among strains and that these differences in GAG binding
result in differences in cell-type-specific binding.
MATERIALS AND METHODS
Bacterial strains and cell lines. The strains used in this study are described in
Table 1. All strains of Borrelia spp. were cultured in MKP base medium (MKP-S)
(26) supplemented with 7% human serum, as described previously (3, 24). The
cell lines used in this study are described in Table 2. Vero (monkey kidney
epithelial) cells were cultured in RPMI 1640 supplemented with 10% NuSerum
(Collaborative Research). C6 (rat) glioma cells were cultured in RPMI 1640
supplemented with 8% fetal bovine serum (FBS), and EA-Hy926 cells were
cultured in Dulbecco modified Eagle medium (DMEM; high glucose) supple-
mented with 1% hypoxanthine-aminopterin-thymidine (Gibco-BRL, Bethesda,
Md.) and 10% FBS. Each of the above cell lines was grown at 37°C in an atmo-
* Corresponding author. Mailing address: Department of Molecular
Genetics and Microbiology, University of Massachusetts Medical Cen-
ter, 55 Lake Avenue North, Worcester, MA 01655. Phone: (508) 856-
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sphere containing 5% CO2. 293 (human kidney) cells were cultured in a 1:1 mix
of DMEM (low glucose; Gibco-BRL) and Ham’s F12 medium (Gibco-BRL)
supplemented with 10% FBS and grown at 37°C in an atmosphere containing 7%
CO2.
Labeling of B. burgdorferi. Radiolabeled B. burgdorferi strains were prepared
by growth in modified MKP medium supplemented with 50 to 100 mCi of [35S]
methionine and [35S]cysteine per ml. Briefly, 100 ml of methionine-free RPMI
1640 with L-glutamine was supplemented with 0.6 g of HEPES, 0.07 g of sodium
citrate, 0.3 g of dextrose, 0.08 g of sodium pyruvate, 0.04 g of N-acetylglucos-
amine, and 0.2 g of sodium bicarbonate and adjusted to pH 7.6. Then, 20 ml of
7% gelatin, 7 ml of pooled human sera, 6.1 ml of 20% bovine serum albumin
(BSA), and 3.75 ml of 8% neopeptone, all of which had been dialyzed against
phosphate-buffered saline (PBS), were added to the medium. This methionine-
free medium was supplemented with 35S-labeled protein labeling mix (NEG-072;
NEN Dupont, Wilmington, Del.) to a final concentration of 50 to 100 mCi/ml and
then sterilized by filtration through a 0.22-mm (pore size) filter. B. burgdorferi
cultures were concentrated by centrifugation and added to the labeling medium
at a concentration of approximately 5 3 108 bacteria per ml. After 6 to 8 h of
growth at 33°C, the culture was diluted 1:10 in MKP medium and cultured
overnight at 33°C. The bacteria were washed, concentrated by centrifugation for
15 min at 15,000 3 g, washed again, and stored as aliquots at 280°C in MKP-S
containing 20% glycerol, as described earlier (3).
GAG-mediated attachment of labeled spirochetes to mammalian cells. (i) Bac-
terial binding assays. One to two days prior to each assay, the mammalian cells
to be tested were lifted with 0.05% trypsin–0.53 mM EDTA (Gibco-BRL) and
plated in Nunc 96-well breakapart microtiter plates coated with Yersinia pseudo-
tuberculosis invasin protein, which promotes cell attachment by binding a subset
of b1-chain integrins (18). Just prior to the addition of bacteria, confluent cell
monolayers were washed twice in PBS (150 mM NaCl, 16.9 mM K2HPO4, 4.8
mM KH2PO4; pH 7.4). Frozen aliquots of radiolabeled bacteria were thawed,
suspended at 1 3 108 to 2 3 108/ml in MKP-S, and incubated for 2 h at room
temperature to allow for physiologic recovery of the bacteria. Dark-field micros-
copy indicated that in all cases, more than 90% of the spirochetes showed intact
morphology and vigorous motility. The bacteria were diluted 1:3 into 10 mM
HEPES–10 mM glucose–50 mM NaCl (pH 7.0) and added to quadruplicate wells
at approximately 106 bacteria/well. To promote host cell-bacterium contact, the
microtiter plates were centrifuged at 190 3 g for 5 min at 20°C and then rocked
at 20°C for 1 h. Unbound bacteria were removed by washing the monolayers
three times in PBS supplemented with 0.2% BSA. After the integrity of the
monolayers was confirmed microscopically, the plates were air dried, and bound
bacteria in each well were quantitated by liquid scintillation. For each assay, the
bacterial binding to identically treated wells without mammalian cells was de-
termined, and this value was always less than 2%.
(ii) Inhibition with exogenous GAGs or an inhibitor of proteoglycan synthesis.
To test the effect of exogenous GAGs on bacterial attachment, radiolabeled
bacteria were incubated for 30 min at room temperature in MKP-S supplement-
ed with various concentrations of GAGs and diluted 1:3 into 10 mM HEPES–10
mM glucose–50 mM NaCl (pH 7.0) prior to the addition of bacteria to mono-
layers. Heparin, chondroitin-4-sulfate, chondroitin-6-sulfate, and dermatan sul-
fate were purchased from Sigma Chemical Co. (St. Louis, Mo.). To inhibit the
addition of heparan sulfate and chondroitin sulfate GAGs to the protein core of
proteoglycans, mammalian cells were cultured overnight in medium supplement-
ed with 5 mM p-nitrophenyl-b-D-xyloside (Sigma) or, as a control, 5 mM p-nitro-
phenyl-a-D-galactoside (19, 24).
(iii) Inhibition by enzymatic removal of specific classes of GAG. The effect of
enzymatic removal of different classes of GAGs on bacterial attachment was
determined as previously described (22). Briefly, monolayers were incubated
with 0.5 U of heparinase I, heparitinase (heparinase III), or chondroitinase ABC
(all from Sigma) per ml for 2 h at 37°C in RPMI 1640 supplemented with 1%
BSA, 1022 trypsin inhibitory units of aprotinin per ml, and 150 mg of phenyl-
methylsulfonyl fluoride per ml. The conditions for lyase treatment were previ-
ously shown to (i) specifically release 35S-labeled GAG from the monolayer
surface (22) and (ii) result in maximal inhibition of binding to 293 and C6 cells,
i.e., a level of binding indistinguishable from the binding to empty wells or to cells
treated with an inhibitor of proteoglycan synthesis (e.g., see Fig. 5). In addition,
multiple B. burgdorferi strains were tested in parallel, and each lyase inhibited
binding by at least one strain, indicating that all lyases were enzymatically active
in each experiment. Each strain was assayed on at least three separate occasions.
(iv) Statistical analysis. The statistical significance of differences in bacterial
binding after mock versus lyase or xyloside treatment of monolayers or in the
presence versus the absence of exogenous GAG was determined by two-tailed
t-test analysis with Microsoft Excel version 4.0.
RESULTS
Lyme disease spirochetes vary in their dependence on GAGs
for attachment to Vero cells. B. burgdorferi N40 clone D10/E9
(herein simply referred to as N40), a low-passage infectious
strain, was previously shown to bind Vero cell GAGs much
more efficiently than HB19 clone 1, a high-passage noninfec-
tious strain (22). To test whether other Lyme disease strains
varied in their ability to recognize GAGs, we examined GAG
binding by a collection of seven other Lyme disease strains,
which included other high-passage derivatives of HB19, as well
as genetically diverse Lyme disease spirochetes (Tables 1 and
3). We initially tested GAG-binding by using the fibroblast-like
Vero cells, a cell line we have previously used extensively for
this purpose (22).
Binding by a different high-passage clone of HB19 (herein
referred to as HB19-W) and HB19-R1 (a derivative of HB19-
W that does not express the major outer surface proteins OspA
or OspB [28]) bound very well to Vero cells, in contrast to
HB19 clone 1 (Fig. 1). Exogenous GAGs did not inhibit bind-
ing by HB19-W and HB19-R1 (Table 3), suggesting that these
strains may bind to Vero cells in a GAG-independent manner.
Consistent with this hypothesis, the enzymatic removal of dif-
ferent classes of GAG with specific lyases had no effect on cell
binding by these strains, in spite of the fact that parallel diges-
tions of Vero cells significantly diminished binding by other
Lyme disease strains (Fig. 1; see also Fig. 2 and 3). Combining
lyase treatment with two other treatments to inhibit GAG-me-
diated attachment (i.e., the inhibition of proteoglycan synthesis
with b-xyloside and the addition of the GAG-binding protein
platelet factor 4) also had no effect on binding by HB19-W and
HB19-R1 (data not shown). The binding phenotypes of the
TABLE 1. Bacterial strains used in this study
Straina No. ofpassagesb Source or reference
B. burgdorferi sensu stricto
N40 clone D10/E9 8 5, 21
HB19-W High A. Barbour (28)
HB19-R1 High A. Barbour (28)
HB19 clone 1 High 21
CA20-2A 6 P. Rosa (5, 27)
B. garinii PBi 8 V. Preac-Mursic (5, 34)
B. afzelii PBo 8 V. Preac-Mursic (5, 34)
B. afzelii VS461 13 V. Preac-Mursic (5, 25)
a The Lyme disease spirochetes B. burgdorferi sensu stricto, B. garinii, and B.
afzelii are members of B. burgdorferi sensu lato (33).
b High, greater than 50 passages.
TABLE 2. Cell lines used in this study
Cell line Cell type Predominant GAG recognizedby B. burgdorferi N40a Source or reference
Vero Kidney fibroblast-like Heparan sulfate ATCC (CCL 81)
293 Kidney epithelial Dermatan sulfate ATCC (CRL 1573)
C6 Glial Dermatan and heparan sulfate ATCC (CCL 107)
EA-Hy926 Endothelial Heparan sulfate 8
a Identified by effect of specific lyase digestion of monolayers on binding by B. burgdorferi N40 (24).
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three HB19 derivatives suggest that different derivatives of the
same strain differ significantly in their cell-binding activities
and that HB19-W and HB19-R1 bind Vero cells predominant-
ly via a GAG-independent mechanism.
Vero cell binding by the other strains (N40, CA20-2A, PBi,
and VS461) was blocked by exogenous GAG, and in each case,
the 50% inhibitory concentration (IC50) for the heparin (a
heparan sulfate analog) was lower than for the dermatan sul-
fate (Table 3). The more potent inhibitory activity of heparin
compared to dermatan sulfate in this assay could simply re-
flect the greater negative charge of heparin. In order to
determine the preference of GAG recognition among these
strains, Vero cell attachment by a number of spirochete strains
was measured after enzymatic cleavage of specific classes of
GAGs by using various lyases. Heparinase was used for the
removal of heparin-related GAGs, heparitinase for heparan sul-
fate-related GAGs, and chondroitinase ABC for dermatan and
chondroitin sulfates. In addition to examining N40, CA20-2A,
PBi, and VS461, the GAG-binding preference of B. afzelii PBo
was assessed.
As previously shown, heparin/heparan sulfate GAGs pri-
marily mediated attachment of strain N40 to Vero cells, be-
cause attachment was inhibited by treatment with heparinase
or heparitinase, while chondroitinase ABC had no effect (ref-
erence 22 and Fig. 2). The inhibition of binding by heparinase
or heparitinase digestion was not complete, likely reflecting the
expression of a GAG-independent binding pathway by this
strain (4, 14). Consistent with this hypothesis, combination
lyase digestion had no greater inhibitory effect than heparinase
or heparitinase digestion alone (Fig. 3). The mechanism of
Vero cell attachment by strains CA20-2A and PBi resembled
that of strain N40, in that binding by these strains was also in-
hibited better by heparinase and heparitinase than by chon-
droitinase ABC (Fig. 2).
Analysis of the last two strains, PBo and VS461, indicated al-
ternate GAG-binding preferences: attachment of both strains
was inhibited by chondroitinase ABC digestion, indicating that
dermatan or chondroitin sulfates were required for maximal
binding (Fig. 2). Heparinase and heparitinase digestion of
Vero cells also resulted in a significant decrease in binding by
strain PBo, indicating a mixed GAG binding preference for
FIG. 1. High-passage derivatives of strain HB19 display no GAG-dependent
binding to Vero cells but differ in their cell attachment activity. Prior to the
addition of radiolabeled bacteria, Vero cells were mock treated or were treated
with the indicated lyase (see Materials and Methods). Hep., heparinase diges-
tion; Hpt., heparitinase digestion; Chon. ABC, chondroitinase ABC digestion.
To ensure that all lyases were enzymatically active in each experiment, multiple
strains were tested in parallel, and each lyase inhibited binding by at least one
strain (see Fig. 2 and Materials and Methods). Each bar represents the aver-
age 6 the standard deviation (SD) of four determinations.
FIG. 2. The species of GAGs that promote attachment of Lyme disease
spirochetes to Vero cells varies with bacterial strain. Prior to the addition of
radiolabeled bacteria, Vero cells were mock treated or were treated with the
indicated lyase. Hep., heparinase digestion; Hpt., heparitinase digestion; Chon.
ABC, chondroitinase ABC digestion. Controls to ensure that all lyases were
enzymatically active in each experiment were performed as described in the Fig.
1 legend and in Materials and Methods. Each bar represents the average 6 the
SD of four determinations. Significant (P , 0.05) differences in binding to mock-
versus lyase-treated monolayers were determined by t-test analysis and are indi-
cated by asterisks. Each strain was assayed on at least three separate occasions,
and a representative experiment is shown.
TABLE 3. Heparin and dermatan sulfate inhibit Vero cell binding by a subset of Lyme disease spirochetes
Inhibitor
IC50 (mg/ml)a for strain:
N40 CA20-2A PBi VS461 HB19-W HB19-R1 HB19 clone 1
Heparin 8.0 1.9 3.0 0.4 .500 .500 NAb
Dermatan sulfate 32 32 50 35 .500 .500 NA
Chondroitin-6-sulfate .500 .500 .500 .500 .500 .500 NA
Chondroitin-4-sulfate .500 .500 .500 .500 .500 .500 NA
a Attachment of B. burgdorferi sensu lato strains to Vero cells was determined in the presence of various concentrations of GAG (see Materials and Methods). IC50
indicates the estimated concentration of GAG at which bacterial binding is 50% of the level of binding in the absence of inhibitor. The percentages of spirochetes bound
in the absence of inhibitors were as follows: N40, 21.4 6 1.3%; CA20-2A, 7.1 6 0.8%; PBi, 11.4 6 0.8%; VS461, 17.3 6 2.0%; HB19-W, 36.1 6 0.9%; HB19-OspR1,
32.3 6 1.4%.
b NA, not applicable (this strain does not bind Vero cells [22]).
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this strain. VS461 binding was inhibited only slightly by he-
parinase, suggesting that dermatan or chondroitin sulfates
are likely to play the more important role than heparan sulfate
in host cell recognition by this strain.
High-passage B. burgdorferi clone 1 recognizes dermatan sul-
fate better than heparin. The high-passage strain B. burgdorferi
HB19 clone 1 was previously demonstrated to express very
little heparin-binding activity and to attach inefficiently to Vero
cells (Fig. 1 and reference 22). The finding that different Lyme
disease strains express variant GAG-binding preferences raised
the possibility that HB19 clone 1 may bind GAGs but not the
specific GAGs that are expressed by Vero cells. Indeed, as
previously shown (4), this strain efficiently bound 293 cells
(14.5% of inoculum bound) (Fig. 4A). Dermatan or chon-
droitin sulfate primarily mediated bacterial attachment to 293
cells, because digestion with chondroitinase ABC diminished
bacterial binding, whereas digestion with heparinase or hep-
aritinase alone had little effect. Nevertheless, HB19 clone 1
apparently has the ability to (weakly) bind heparin or heparan
sulfate, because heparinase or heparitinase when used in com-
bination with chondroitinase ABC had significant inhibitory
effects on HB19 clone 1 attachment (Fig. 4A).
That HB19 clone 1 preferentially binds dermatan sulfate was
further demonstrated by inhibition of 293 cell attachment with
exogenous GAGs. Dermatan sulfate was a much better inhib-
itor of HB19 clone 1 attachment than was heparin (Fig. 4B;
Table 4). In contrast, N40 attachment to 293 cells was inhibited
better by heparin than by dermatan sulfate.
B. burgdorferi strains that express different GAG binding
preferences display different binding preferences for cultured
glial and endothelial cells. It was previously shown that the
binding of B. burgdorferi N40 to cultured endothelial cells was
mediated primarily by heparan sulfate, whereas binding to glial
or neural cells was mediated by both heparan and dermatan
sulfates (Table 2 and reference 24). Thus, N40 bound efficient-
ly to the endothelial cell line EA-Hy926 in a heparitinase-
inhibitable manner (Fig. 5A) and to C6 glioma cells in a hep-
aritinase- and chondroitinase-inhibitable manner (Fig. 5B).
We postulated that preferential recognition of dermatan
sulfate by strains such as HB19 clone 1 could result in the
preferential attachment to glial cells compared to endothelial
cells. Indeed, HB19 clone bound well to C6 cells but not to
EA-Hy926 cells (Fig. 5). GAG binding was responsible for
HB19 clone 1 attachment to C6 glioma cells because attach-
ment was almost completely inhibited by b-xyloside, an inhib-
itor of GAG synthesis, or by digestion with a combination of
heparitinase and chondroitinase ABC (Fig. 5B). Chondroiti-
nase ABC digestion had a somewhat greater effect on bacterial
attachment than did heparitinase digestion. The critical GAG
chain removal from the glial cells by chondroitinase ABC is
likely to be dermatan sulfate, because exogenous dermatan
sulfate inhibited HB19 clone 1 attachment to these cells, where-
as chondroitin-4-sulfate or chondroitin-6-sulfate did not (data
not shown). These results suggest that both N40 and HB19
clone 1 can bind glial cells primarily by recognizing dermatan
sulfate, but HB19 clone 1, by virtue of its relative inability to
FIG. 3. A component of N40 attachment to Vero cells is independent of
GAGs. Vero cells were mock treated or were treated with the indicated lyases
prior to the addition of radiolabeled strain N40. Hep., heparinase digestion;
Hpt., heparitinase digestion; Chon. ABC, chondroitinase ABC digestion. Each
bar represents the average 6 the SD of four determinations. Significant (P ,
0.05) differences in binding to mock- versus lyase-treated monolayers were de-
termined by t-test analysis and are indicated by asterisks.
FIG. 4. Strains N40 and HB19 clone 1 demonstrate differences in their pref-
erences for dermatan sulfate or heparin. (A) 293 cells were mock treated or were
treated with the indicated lyase(s) prior to the addition of radiolabeled bacteria,
and the percent bound bacteria was determined (see Materials and Methods).
Hep., heparinase digestion; Hpt., heparitinase digestion; Chon. ABC, chondroiti-
nase ABC digestion. Each bar represents the average 6 the SD of four deter-
minations. Significant (P , 0.05) differences in binding to mock- versus chon-
droitinase-treated monolayers were determined by two-tailed t-test analysis and
are indicated by single asterisks. Double asterisks indicate significant differences
in binding to chondroitinase versus combination lyase digestions. (B) Attach-
ment of strain N40 and HB19 clone 1 was determined in the presence of various
concentrations of heparin or dermatan sulfate (see Materials and Methods).
Binding is expressed relative to the binding in the absence of inhibitor. In the
experiment shown, the binding of N40 in the absence of inhibitor was 28.1% of
the inoculum, and binding of HB19 clone 1 was 16.4%.
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recognize heparan sulfate, is not able to bind to EA-Hy926
cells.
If the selective binding to glial cells by HB19 clone 1 and the
“promiscuous” binding to both glial and endothelial cells by
N40 are reflections of their GAG-binding preferences, then
the GAG-binding preferences of the other strains character-
ized in this study should also correlate with selective or pro-
miscuous binding. Assessment of the binding of strains PBi,
PBo, and VS461 to C6 and EA-Hy926 cells confirmed this
prediction. On the basis of lyase digestion, VS461 bound Vero
cells primarily via dermatan sulfate (Fig. 2), and this strain, like
HB19 clone 1, bound to C6 glioma cells but not EA-Hy926
cells (Table 5). Strain PBi, like N40, recognized primarily
heparan sulfate on Vero cells and bound well to both C6 and
EA-Hy926 cells. Strain PBo displayed a mixed GAG-binding
preference on Vero cells, requiring both dermatan sulfate and
heparan sulfate for maximal binding—this strain also ex-
pressed an intermediate selectivity of cell attachment, binding
to glial cells efficiently and to EA-Hy926 cells poorly but above
the background levels. Assessment of cell binding after lyase
digestion of C6 and EA-Hy926 cells revealed that, as predict-
ed, chondroitin or dermatan sulfates played a more important
role than heparan sulfate in C6 glioma attachment by all of
the strains (Table 5). Similarly, for the two strains proficient at
binding EA-Hy926 cells (PBi and PBo), endothelial cell attach-
ment depended upon heparan sulfate.
DISCUSSION
Initiation and maintenance of infection of a host by various
pathogens often involves interactions between microbial and
eukaryotic surface components (10). B. burgdorferi has been
shown to recognize GAGs on the surface of cultured mamma-
lian cells (17, 22). GAGs are ubiquitously expressed on the
surface of mammalian cells and in extracellular matrix, and we
undertook this study to investigate whether the preference for
different species of GAG varies among Lyme disease spiro-
chetes and to examine the potential contribution of GAG
recognition to cell-type-specific attachment.
Diverse Lyme disease spirochetes were tested for GAG rec-
ognition. Lyme disease spirochetes express multiple pathways
for attachment to cells and matrix (3, 12, 15), and two high-
passage derivatives of HB19 (HB19-W and HB19-R1) bound
well to Vero cells in a GAG-independent manner. Another
high-passage derivative of HB19 (HB19 clone 1) did not bind
Vero cells at all. Thus, none of the high-passage HB19 deriv-
atives could be demonstrated to recognize Vero cell GAGs.
Isaacs previously used HeLa cells to show that low-passage
HB19 expressed a GAG-binding activity that was apparently
lost or modified upon in vitro culture (17).
Binding of each of the other five strains to Vero cells was
diminished by exogenous GAGs and/or by enzymatic digestion
of GAGs from the cell surface. The removal of different classes
FIG. 5. Different GAG binding preferences of Lyme disease spirochetes lead to differences in cell-type-specific binding. (A) Empty wells, untreated, or lyase-treated
EA-Hy926 cells were incubated with radiolabeled strain N40 (solid bars) or HB19 clone 1 (hatched bars), and the percent bound bacteria was determined (see Materials
and Methods). Each bar represents the average 6 the SD of four determinations. (B) Empty wells (No cells) and untreated (No inhib.), mock-, or lyase-treated C6
glioma cells or C6 glioma cells grown in the presence of the GAG synthesis inhibitor p-nitrophenyl-b-D-xyloside or the control sugar p-nitrophenyl-a-D-galactoside were
incubated with radiolabeled strain N40 (solid bars) or HB19 clone 1 (hatched bars), and the percent bound bacteria was determined. Significant (P , 0.05) differences
in binding to mock- versus lyase- or b-D-xyloside-treated monolayers were determined by t-test analysis and are indicated by asterisks.
TABLE 4. Different GAG inhibition profiles expressed
by two B. burgdorferi strains
Inhibitor
IC50 (mg/ml)a for strain:
N40 HB19 clone 1
Heparin 1.3 .500
Dermatan sulfate 60 18
Chondroitin-6-sulfate .500 .500
Chondroitin-4-sulfate .500 .500
a Attachment of B. burgdorferi N40 and HB19 to 293 cells was determined in
the presence of various concentrations of GAG (see Materials and Methods).
IC50 indicates the estimated concentration of GAG at which bacterial binding is
50% of the level of binding in the absence of inhibitor. The percentages of the
spirochetes bound in the absence of inhibitors were as follows: N40, 28.3 6 2.8%;
HB19 clone 1, 18.1 6 2.7%.
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of GAGs from the surface of Vero cells resulted in strain-spe-
cific effects on spirochetal binding and indicated several differ-
ent GAG-binding preferences among the strains, including the
following: (i) N40, CA20-2A, and PBi recognized predominant-
ly heparin/heparan sulfate on the surface of Vero cells; (ii)
PBo bound to Vero cells by using both heparan sulfate and der-
matan sulfate; and (iii) VS461 attached to Vero cells primarily
via a chondroitinase ABC-sensitive GAG chain(s), presumably
dermatan sulfate. The ability of strain VS461 to recognize der-
matan sulfate better than does strain N40 is consistent with the
previous observation that VS461, but not N40, efficiently bound
to CHO-pgsD cells, which express galactosaminoglycans but not
glucosaminoglycans (9, 22).
HB19 clone 1 provided the clearest evidence of an alternate
GAG-binding preference because it did not recognize Vero
cell GAGs yet still bound well to dermatan sulfate GAGs ex-
pressed by 293 cells. Binding to 293 cells was inhibited better
by exogenous dermatan sulfate than by heparin. It was previ-
ously shown that charge is a critical determinant for recogni-
tion of GAGs by B. burgdorferi (17, 22, 23), but the finding that
HB19 clone 1 recognizes dermatan sulfate better than the
more highly charged GAG heparin indicates that the structure
of the glycan backbone of the GAG is likely to play an addi-
tional role in bacterial binding.
It is important to note that although different Lyme disease
strains clearly vary in their relative preferences for heparan
sulfate or dermatan sulfate, these preferences are not absolute,
and nearly all of the strains retain some ability to recognize
both GAGs. With the exception of HB19 clone 1, cell attach-
ment was inhibited by either exogenous heparin or dermatan
sulfate. In addition, for the strains tested (N40, HB19 clone 1,
VS461, and PBo), enzymatic removal of both glucosaminogly-
cans and galactosaminoglycans diminished cell attachment to a
greater extent than removal of either class alone (Fig. 3 and 4
and data not shown). The ability to bind more than one class of
GAG is typical of GAG-binding receptors (20).
The variation in GAG-binding preference could be ex-
plained by hypothesizing that the Lyme disease spirochete
expresses a single GAG-binding receptor but that strain vari-
ations in this receptor result in different GAG-binding prefer-
ences. An alternative model is that some strains (such as N40)
express multiple GAG receptors, each specific for a particular
class of GAGs, while other strains (such as HB19 clone 1) ex-
press only a receptor for dermatan sulfate. Complicating the
analysis of GAG binding still further are the observations that
(i) an uncloned version of B. burgdorferi N40 expresses two
proteins that bind decorin, a collagen-associated chondroitin
or dermatan sulfate proteoglycan (15, 16), and (ii) B. burgdor-
feri B31 binds aggrecan, a cartilage chondroitin sulfate proteo-
glycan (18a). Neither heparin nor aggrecan efficiently blocked
binding of uncloned N40 to decorin (15), and dermatan sulfate
did not efficiently inhibit B31 attachment to aggrecan (18a),
findings consistent with the bacterial expression of multiple
proteoglycan- and GAG-binding pathways. Ultimately, an un-
derstanding of the relationships between these binding activi-
ties will require further characterization of all of the bacterial
molecules involved. The recent cloning of decorin-binding pro-
teins should facilitate this analysis (15).
It has been suggested that different strains of Lyme disease
spirochete are associated with different clinical manifestations
of the illness (1, 2, 33). The results presented here demonstrate
that the differences in GAG-binding preferences among strains
can result in differences in cell-type-specific binding in vitro.
The relationship between attachment of in vitro-cultured bac-
teria to mammalian cells and infection of particular tissues re-
mains to be defined, and no determinants of tissue tropism have
yet been identified for this pathogen. Determining whether
attachment to specific cell types in vitro is related to the col-
onization of particular tissues during infection will require
further study.
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